In a post hoc analysis of QUAZAR AML-001 phase 3 trial (NCT01757535), 66 patients with FLT3-mutated AML (46 patients with FLT3-ITD) were treated with oral azacitidine and the median OS was prolonged in FLT3-mutated AML patients compared to the placebo group (28.2 months vs 9.7 months). The gene discussed is FLT3; the disease is acute myeloid leukemia.